Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
about
Procarbazine, lomustine and vincristine for recurrent high-grade gliomaAdjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomasIDH1 and IDH2 mutations in gliomasExternal beam radiation dose escalation for high grade gliomaHigh-grade glioma management and response assessment-recent advances and current challengesCurrent status of biomarker research in neurologyROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic StrategiesImaging of oligodendrogliomaRecent Molecular Advances in Our Understanding of GliomaClinical management of grade III oligodendrogliomaMalignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methodsOligodendroglioma: pathology, molecular mechanisms and markersMolecular biology of high-grade gliomas: what should the clinician know?Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesMolecular heterogeneity in glioblastoma: potential clinical implicationsMolecular Markers in Low-Grade Glioma-Toward Tumor ReclassificationPhase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumorsNeuro-oncology: Five new things.Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.Brainstem oligodendroglial tumors in children: two case reports and review of literatures.Joint modeling of longitudinal health-related quality of life data and survival.Pros and cons of current brain tumor imagingParadoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging.Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors.IDH mutations: genotype-phenotype correlation and prognostic impact.Oligodendrogliomas in pediatric and adult patients: an outcome-based study from the Surveillance, Epidemiology, and End Result databaseIDH1(R132H) mutation increases U87 glioma cell sensitivity to radiation therapy in hypoxia.Actionable molecular biomarkers in primary brain tumors.Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured PopulationProspective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant GliomaGenetic landscape of extreme responders with anaplastic oligodendroglioma.Does early resection of presumed low-grade glioma improve survival? A clinical perspective.Morphologic spectrum of glial tumors: an increased trend towards oligodendroglial tumors in Pakistan1p/19q testing has no significance in the workup of glioblastomas.Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma.
P2860
Q24187436-C5B4BE39-FE32-4A0D-9F50-5F487858126AQ24194645-B604B4ED-1336-4A00-9035-96DE7E63D33FQ24561928-73225E41-9D4E-44EC-88C6-1D59509429F2Q26470382-6082715B-C6A6-4975-9692-9C6FB71A4808Q26740664-36476328-7763-4745-B196-5771A6C2BFD0Q26744505-B0DB4D7C-2F0A-41CC-BB79-744919191C4DQ26747496-1545EFAC-F4F5-46DB-A1F4-2EDBE49842B1Q26768596-7B5EEE5B-7AFC-4B39-B7FF-E3968330853BQ26798442-806464BB-76B1-4D9A-ACE6-56B40FEAFD32Q26801254-EF04D45A-2A3B-40D7-8911-9AF35BC345C8Q26853516-CBB7B849-A362-4B19-A853-72EDA32CD386Q27002448-44677F03-7A2F-4F4A-92C6-C47BF9E57C36Q27009190-21DE4E8A-EDC0-41DD-8FF4-85AC47A7374EQ27853175-1E49BCC0-C852-477B-8ECA-11AEE8D79BABQ28066926-A370D3AE-9AD2-41D7-B2CB-9A57E5B6A3B1Q28088605-F83D4E44-392F-41B3-8EE2-8E6F4F74EC25Q28383205-2D8DEB7C-8375-4E5E-BE19-90FC25D83374Q30275188-B2C1FE2C-2F21-4BC3-B95C-8727F9B06D9EQ30370204-F291A32B-1E67-4EA4-840D-50212B378621Q30415098-A3E8DB9B-E232-4B47-AAEE-DA51A8436CD2Q30836702-3159C25F-8F40-4921-A8D7-8F3C9AF9267BQ30857294-43AE4686-B38E-4D82-9287-D3A864B92208Q30859974-8AF90EF2-865E-4035-A062-5B405D317455Q30860126-B7F17B75-C94D-42AC-B910-B9B10E9DC32DQ30984368-D7801575-164E-4B3C-BB67-DC65EDFFB1BEQ33419628-5F006BB6-7182-43CB-9416-3DF4F6986275Q33439379-80956D79-9A88-4295-B55C-233B8E1BFE4CQ33599587-BDB20934-CBEC-439A-B514-1973B0AD5384Q33615867-57FAF781-064D-4989-8B90-4B207242819CQ33649896-602C4314-188A-49AE-A4A1-C48959E13303Q33660428-FB6C2305-1C2C-469F-877B-E9244B61E76AQ33772355-6A2E17F7-A872-46C3-9847-35249477BCA0Q33804713-489CEF16-41E9-4D42-BD14-0D94564892E8Q33805484-F724EC28-5506-4543-B68D-1BFAD73B364BQ33816600-3BCCA77F-5F80-49C6-A140-EE87AB3F6FB7Q33829209-1B48D343-8721-4EFC-8672-6B54761EECBBQ33867304-68BBF8AC-76B7-4AD9-AA4F-679267267E22Q33869758-ED1F45D8-4C00-442F-9609-C39F93A63197Q33893445-49755AEE-694A-4677-B7AA-D64E47595EE8Q33906012-DBB3AD1A-E2C9-459A-AA06-8378770A1A78
P2860
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Adjuvant procarbazine, lomusti ...... brain tumor group study 26951.
@ast
Adjuvant procarbazine, lomusti ...... brain tumor group study 26951.
@en
Adjuvant procarbazine, lomusti ...... brain tumor group study 26951.
@nl
type
label
Adjuvant procarbazine, lomusti ...... brain tumor group study 26951.
@ast
Adjuvant procarbazine, lomusti ...... brain tumor group study 26951.
@en
Adjuvant procarbazine, lomusti ...... brain tumor group study 26951.
@nl
prefLabel
Adjuvant procarbazine, lomusti ...... brain tumor group study 26951.
@ast
Adjuvant procarbazine, lomusti ...... brain tumor group study 26951.
@en
Adjuvant procarbazine, lomusti ...... brain tumor group study 26951.
@nl
P2093
P50
P921
P356
P1476
Adjuvant procarbazine, lomusti ...... brain tumor group study 26951
@en
P2093
Anouk Allgeier
Cees C Tijssen
Charles J Vecht
Denis Lacombe
Hans J J A Bernsen
Jean-Yves Delattre
Johan M Kros
Khê Hoang-Xuan
László Sipos
Marc Frenay
P304
P356
10.1200/JCO.2012.43.2229
P407
P577
2012-10-15T00:00:00Z